Prevalent deposition of plasma proteins on nano-surface alters the synthetic identity of liposomes in blood circulation. The key plasma protein(s) that can dominate in vivo fate of liposomes are of central importance for preclinical design and precise medication of liposome-based therapeutics. Herein, natural IgM, but not IgG, is identified to ubiquitously absorb on liposomal surface and takes the lead in complement activation of different species. The absorbed natural IgM, which negatively correlates with the in vivo performance of liposomes, becomes a potential indicator to guide the de novo design and optimization of liposomes. More importantly, the varying natural IgM levels in cancer patients may be one of the causal factors for clinical differences in response to liposome-based therapeutics. Clinical monitoring of the natural IgM level and its binding with liposomes becomes crucial to optimize the therapeutic regimen prior to the application of liposome-based therapeutics.

中文翻译：

---

天然IgM决定了脂质体的体内性能。

血浆蛋白在纳米表面上的普遍沉积改变了血液循环中脂质体的合成身份。可以控制脂质体体内命运的关键血浆蛋白对于基于脂质体的治疗剂的临床前设计和精确药物治疗至关重要。在此，天然IgM而非IgG被鉴定为在脂质体表面上普遍吸收，并在不同物种的补体激活中起主导作用。与脂质体的体内性能负相关的吸收的天然IgM成为指导从头设计和优化脂质体的潜在指标。更重要的是，癌症患者体内不同的天然IgM水平可能是对基于脂质体的治疗药物产生临床差异的原因之一。